Abstract: Torsade de pointes (TdP) is increasingly recognized as a complication of drug therapy. The most common cause of drug-induced QT prolongation is inhibition of the rapidly activating component of the delayed potassium current (I(Kr)). Moxifloxacin, a widely used fluoroquinolone, is a weak I(Kr) inhibitor and has been associated with QT prolongation. We report a case of marked QT prolongation (618 ms) and TdP associated with moxifloxacin use. Although it is difficult to predict which patients are at risk from TdP, careful assessment of the risk/benefit ratio is important before prescribing drugs known to cause QT prolongation.
Publication Year: 2008
Publication Date: 2008-01-01
Language: en
Type: article
Indexed In: ['pubmed']
Access and Citation
Cited By Count: 34
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot